Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.59 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27623107 | 0.82 | HTT (0.45) | ANPEPMMEATML3MBTL1 | |
| SCHEMBL9386926 | 0.79 | ANPEP (0.60) | ANPEPMMP2MMP9 | |
| SCHEMBL7268268 | 0.79 | ANPEP (0.60) | ANPEPMMP2MMP9 | |
| SCHEMBL6105902 | 0.79 | ANPEP (0.60) | ANPEPMMP2MMP9 | |
| SCHEMBL3448513 | 0.78 | MAPK1 (0.56) | FPR2MME | |
| SCHEMBL1983999 | 0.78 | LMNA (0.47) | ANPEPATML3MBTL1 | |
| SCHEMBL3448516 | 0.78 | MAPK1 (0.56) | FPR2MME | |
| SCHEMBL3381057 | 0.78 | LMNA (0.47) | ANPEPATML3MBTL1 | |
| SCHEMBL29430352 | 0.78 | LMNA (0.47) | ANPEPATML3MBTL1 | |
| SCHEMBL7400542 | 0.77 | CTSL (0.70) | ANPEPFPR2CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| CN-101896461-A | Gamma secretase modulators | AMGEN INC | 2010-11-24 | — | — | CN | disclosed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | ANPEP 150/4885FPR2 3441/4885MME 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.